Loading…
Based on limited metadata, Quadrant Sales & Marketing, Inc. received an FDA Warning Letter on May 28, 2020 regarding drug products. Without access to the full letter text or specific subject line, the precise nature of the violations cannot be determined from the metadata provided. The letter falls under FDA's drug product regulatory authority, though the specific issuing office is not documented in the available information. To understand the actual violations cited, the complete Warning Letter text would need to be reviewed.